Severe psoriasis referrals

Providing care and management for adults with severe psoriasis

Contact details

Shanti Martin
0207 188 6417

Severe psoriasis referral address
St John's Institute of Dermatology
1st floor
Counting House
Guy's Hospital
Great Maze Pond
London SE1 9RT

We accept referrals from all medical professionals, including GPs.
Please send your referral to the above address.

Referrals from other hospitals must include a completed Inter-Provider Minimum Data Set or ensure that one is sent within 48 hours of referring a patient.

We aim to see all new patients within eight weeks of receiving referrals.

If your referral is urgent, please contact our assistant service manager Koyinsola Quadry on 020 7188 1901, who can arrange a discussion with our clinic team. 

Referral criteria

We will see patients with:

(i) Plaque psoriasis fulfilling NICE criteria for biologic therapy (ie: PASI 10, DLQI 10, ciclosporin, methotrexate have failed/cannot be used)

(ii) Psoriasis that has failed a second biologic where a supra-specialist opinion is required (as per NICE 153 CG)

(iii) Severe or very severe plaque psoriasis where licensed oral therapies and NICE approved biologic therapy have failed or cannot be used

(iv) Localised forms of psoriasis (eg: palmoplantar pustulosis, acrodermatitis of hallopeau; nail disease) associated with significant functional impairment and/or major impact on patients well being (ie DLQI>10) where standard systemic therapy has failed or cannot be used

(v) Life-threatening forms of psoriasis (generalised pustular psoriasis; erythroderma; unstable psoriasis)

(vi) Severe psoriasis requiring treatment that requires MDT input including but not limited to:

  • psoriasis with psoriatic arthritis where no local combined rheumatology/dermatology clinic is available
  • psoriasis with multi morbidity (ies) that complicate choice and/or use of second or third line therapy (for example, active infection, recent or current history of cancer, liver disease, renal disease, cardiovascular disease)
  • psoriasis in people whose skin disease is associated with important psychological or psychiatric morbidity
  • psoriasis in people whose past or current psoriasis treatments impact on management (for example, multiple skin cancers following PUVA, irreversible ciclosporin-induced nephrotoxicity, hepatic fibrosis).